Member Info for Big_kahuna

AI scan says:

In mining finance, the company typically provides 20–40% equity, and lenders (like DFC/AFC) provide 60–80% debt.

Once you know BRES’ equity slice (£20m), you just back-calculate total capex:

• £20m = 25% equity → total capex £80m

• £20m = 30% equity → total capex £67m

• £20m = 33% equity → total capex £60m

• £20m = 40% equity → total capex £50m

👉 That’s why the realistic Phase-1 capex range is £50–80 million.

It’s simply the full project cost implied by BRES’ £20m equity requirement using standard industry ratios.

Why this size matters

A £50–80m build is extremely small for a graphite mine capable of producing 20,000tpa concentrate + SPG. Most African graphite projects cost £100–200m+, so Orom-Cross sits at the very bottom of the global cost curve, making it:

• easier to finance,

• faster to reach production,

• more attractive to lenders and strategic buyers, and

• likely to deliver very strong DFS economics (high IRR, short payback).

I had to break my buys to get them in, two of the smaller have shown now, I think they won’t show the big boy till close or maybe tomorrow.

I think we are gonna see 8p today, 10p on wed and Thursday the JORC and DFS hit could take us to 14p then a steady march into the 20s.

Time will tell, but won’t take very much time to tell.

📅 DFS timing implications

The RNS fits perfectly with a DFS imminent scenario:

• Consultants: paid

• Workstreams: closed

• Prospectus: refreshed

• Headroom: reset

• Warrants: exercising heavily

• No fundraising: they don’t need cash, because warrant cash is flowing in

This sequence is exactly what you see in the last 72 hours before a DFS release.

I got very excited for a moment there, still rns looks mildly positive but not real impactful.

I’m think we will close above 8p if we are lucky, I know there is a big unreported buy yet to show :)

10p before JORC/DFS would be sweet, I think that will land on Thursday now, but who knows.

They will call me small kahuna at the food bank if this goes wonky

Executed more cunningly than a cunning fox, who has just been appointed head of cunning at oxford university.

I went big, I’m all in.

Oh maybe when we where doing our miners five a side to pass time waiting for the life changing mRE :)

If i’m out I won’t be out for long, unless it goes pair shaped and I won’t have a pension.

I don’t mention other shares on other boards, but will be 2 maybe 3 other miners that are stagnant till q1, I’m only planning to be out for a week, so I think the risk is minimal, I might buy back in double to make it up to them for the insult. I think we are set to more than double this week.

If no rns in the morning then I have two shares I will sell that are lose making at the moment, should be able to get £30k so buy another 400k shares, then sell on dfs surge and buy back the shares I didn’t want to sell and make a tidy profit.

Leaving my million plus intact for takeover talks in q1.

I will be massively over exposed on bres, but those shares won’t move for this year and I can’t see us not moving up this week.

Now I’m hoping the rns is Wednesday.

Folks… you’re not gonna believe this — I JUST got off the phone with China. CHINER!

They called me — ME! — and they were begging, practically crying, saying:

‘Please, Mr President, PLEASE… we want the JORC! We need the JORC! Nobody does JORCs like you do, sir!’

And I said:

‘NO. WRONG.

Uganda’s got it. UGANDA!’

Because let me tell you something — Uganda has the BEST graphite, the BEST grades, the BEST team.

China? They had JORCs for YEARS and they did NOTHING.

Total disaster, folks. Everyone knows it.

But Uganda? They’re winning. WINNING BIG.

And Blencowe? Making JORCs great again.

People are saying they’ve never seen a JORC like it. Tremendous numbers. Beautiful numbers. The kind of JORC China DREAMS about but NEVER gets.

Chartarex. let me tell you something — and the Fake News absolutely HATES when I say this — but BRES is finally doing things the RIGHT way. The Trump way.

The days of those tiny, weak, low-energy RNS’s?

OVER.

Finished.

Just like CNN’s ratings.

People come up to me — big tough miners, calloused hands, tears in their eyes — and they say,

‘Mr President Sir, sir, PLEASE tell BRES to stop releasing those loser reports. They look like they were written by Sleepy Joe’s interns.’

And I tell them:

‘Folks, don’t worry. We’re gonna Make Announcements Great Again.’

And guess what?

They listened.

They ALWAYS listen.

Because BRES is tired of being pushed around by the Fake News bashers who say,

“The JORC isn’t coming.”

“The DFS doesn’t exist.”

These people are STUPID.

These people are PATHETIC.

These people probably work for MSNBC.

Now we’re getting ONE RNS.

A Big, Strong, Beautiful, TOTALLY LEGAL RNS — despite what the Witch Hunt crowd will say.

JORC? It’s in there.

DFS? Oh, it’s in there.

Maybe even a little more, but I can’t say because it’s under SEAL — like my Georgia case.

The Fake News is gonna meltdown:

“Why is BRES winning? Why is the RNS so good? Why is it so strong?”

Because, folks, this is what happens when you stop listening to the failing media and start listening to WINNERS.

This week?

Going to be YUGE.

Bigger than the debates.

Bigger than Truth Social’s valuation — and that’s saying something.

So buckle up.

The Fake News won’t report it, but BRES is about to drop the most powerful RNS you’ve ever seen.

Maybe the most powerful in HISTORY.

I think we will get odd pre Xmas and on the tail of the announcement we will see a partnership deal with Boehringer, Roche/Genentech or Galapagos announced.

Pure speculation but if it unfolds I want seer of 2025 award.

Yeah can’t blame ai for that one, it’s on me, I told it to include 3 for completeness in that second version I posted.

But you can ignore it, only overlaps 2 and 4 in terms of fit.

Evidence That IPF/ILD Companies (JAK, TYK2, TGF-β, LOXL2) Are Actively Seeking Combination Partners – and Why NFX Fits

⸻

1. FDA Position: Combination Therapy Is Now Expected in IPF

The FDA has openly stated that single-pathway agents have limited effect and that they encourage multi-mechanism combination trials in fibrosis. This industry-wide shift increases demand for safe adjunct therapies like NXP002, NXP003 and NXP004.

⸻

2. Why These Companies Need a Partner Like NFX

Big pharma fibrosis portfolios include JAK/TYK2, TGF-β, LOXL2 and integrin drugs — but they lack:

• safe inhaled antifibrotics

• partnerable low-toxicity add-on therapies

• PK-optimised TGF-β modulators

• mechanisms that avoid overlapping toxicity

• reformulated SOC agents

NFX’s assets were engineered to plug these exact gaps.

⸻

3. How Each NFX Drug Aligns With Partner Needs

NXP002 (inhaled pirfenidone): solves tolerability, delivers locally, ideal for pairing with JAK/TYK2/LOXL2/TGF-β assets.

NXP003 (novel antifibrotic): complementary mechanism, clean safety, designed for co-administration with systemic drugs.

NXP004 (enhanced Tranilast): a PK-improved TGF-β modulator with decades of safety data — highly attractive as an upstream fibrosis blocker in combo regimens.

⸻

4. Which Pharma Are Actively Seeking Combination Partners

Boehringer: publicly pushing multi-mechanism fibrosis combinations; lacks an inhaled antifibrotic → NXP002 fits.

Roche: TGF-β/LOXL2 pipeline needs synergistic add-on agents → NXP003/004 fit.

Galapagos: TYK2/JAK ILD assets require an antifibrotic adjunct → NXP002/003.

BMS: combination-focused fibrosis strategy; NXP004 aligns with their TGF-β work.

Pliant: openly exploring combinations; NFX fills pathways they don’t cover.

⸻

5. Direct Signals From Nuformix

NFX have explicitly stated:

• “Assets designed for combination use”

• “Mechanisms complement JAK, TYK2, TGF-β, LOXL2”

• “Partnering discussions underway”

• “NXP004 shows potential with existing antifibrotics”

Their wording mirrors exactly the pathways above — not accidental.

⸻

6. Why a Partner Deal Looks Increasingly Likely

• NFX recently delivered new data to a potential partner.

• ODD is approaching, a common pre-deal milestone.

• Combination-therapy demand in fibrosis is at its highest point in years.

• NFX assets are low-toxicity and easily bolted onto systemic drugs.

• Several big pharma fibrosis pipelines cannot progress without adjunct partners.

Sorry guys, I think the post was correct beyond the wrong drug being referenced but you can replace with nxp002 and 4.

Happy to take the 1st place in the idiot challenge for 2025, am I allowed multiple entries?

• The same principle of combination therapy applies

• But the setting is lung disease, not skin disease

• Partners would be companies with IPF/ILD assets (JAK, TYK2, TGF-β, LOXL2, antifibrotics, etc.)

• Combination therapy makes even more sense in fibrosis because the disease is multi-pathway and multi-driver

🔹 What NFX is doing differently

NFX is no longer pushing NFX-179 as a standalone drug.

The company has shifted to developing it as part of a combination therapy, where NFX-179 is paired with another company’s asset.

That means:

• Trials are being designed for combo regimens, not monotherapy.

• Pharma discussions are now co-development conversations, not straight licensing.

• The asset is being positioned as a plug-in enhancer for multiple partner drugs across different indications.

This is a fundamental strategic pivot — it moves NFX from “single asset biotech” to “combination platform”.

⸻

🔹 How this changes the financial picture

Combination therapy deals typically have bigger numbers, because they create value for both sides:

• Shared development costs → NFX spends less.

• Bigger milestone structures → because combos can target multiple indications.

• Faster regulatory pathway → if the partner’s drug already has safety data.

• Higher valuation → partners value the uplift to their drug as well as NFX-179.

So the financial models move from “one asset, one indication” to multi-indication, multi-partner upside.

⸻

🔹 How this expands the partner universe

This is the big one.

Before:

NFX needed to find one pharma to back a monotherapy.

Now:

ANY company with a dermatology pipeline drug (PDE4, JAK, biologic, steroid, topical immunomodulator) becomes a potential partner — because NFX-179 can enhance multiple mechanisms.

So instead of a narrow partner list, NFX now effectively has a shop window to almost the entire dermatology sector.

More bidders = better leverage.

Biotechs don’t suddenly redesign their development plan around combination therapy unless:

1️⃣ They’ve had inbound interest,

2️⃣ They’re already exploring specific combo pairings, or

3️⃣ A partner has asked for a combo-ready clinical package.

This isn’t the sort of move you make on speculation — it’s the sort you make when real conversations are happening behind the scenes.

They’ve always been tied together, so could be same day and or same rns, but I think it would be more fun to split them up a little.

Either way looks like both gonna hit this week, fingers crossed tomorrow for at least one

I don’t think your posts are genuine, but read the below if they are.

There’s a lot of confusion about the FDA’s 90-day timeline, so here’s the simple truth.

1️⃣ The 90 days is a target, not a fixed deadline

ODD reviews are meant to be completed in 90 days, but it’s a review goal, not a hard legal deadline.

The FDA can and often does go past 90 days with no consequences.

⸻

2️⃣ The clock only counts when the FDA has everything they need

If the FDA asks the company for extra information, the review clock:

⏸️ Stops

It only resumes when the company replies.

This makes real-world timelines easily stretch to 100–180+ days.

⸻

3️⃣ Even with no pauses, FDA can still exceed 90 days

ODD is not a priority review category.

If workloads are heavy or internal checks run long, decisions slip past 90 days.

It’s common and not a sign of trouble.

⸻

4️⃣ Why timing doesn’t matter — the outcome does

ODD is granted when the FDA is satisfied with:

• prevalence justification

• unmet need

• mechanism of action

• clinical reasoning

Calendar timing ≠ signal of success or failure.

⸻

🔹 Note on partnerships

A partner may well be waiting for ODD before signing, for several reasons:

• ODD gives 7 years US market exclusivity → massively boosts the value of the drug

• Tax credits and fee waivers reduce partner development costs

• Non-dilutive grants become available

• ODD is often the final regulatory tick-box before a deal closes

For many pharma companies, ODD simplifies due diligence and reduces risk.

So waiting for ODD before finalising a collaboration is normal industry practice

I’ll put my guess at 27p.

What is everyone else guessing without seeing JORC or dfs.

Careful ltb if there is no risk then it’s already priced in and there will be no reward.